The same month that researchers published confirmatory findings in Nature Biotechnology (NBT) that "rising-star," emerging markets do not represent much of a near-term challenge to U.S. drug developers, the venture capital (VC) firm Domain Associates disclosed a push to help Western countries gain footholds in China.